American Society of Hematology

Figure 3.

$Figure 3. HSCs labeled by Krt18-CreER contribute to steady-state hematopoiesis. (A-D) Longitudinal analysis of YFP+ fraction in the indicated populations at 1 (A), 4 (B), 26 (C), and ∼52 (D) weeks after tamoxifen treatment (n = 4-6). (E-F) Frequencies of YFP+ cells in each population relative to HSCs. (E) Frequencies of YFP+ cells within the LSK fraction relative to HSCs. (F) Relative frequencies of YFP+ myeloid and lymphoid progenitor cells relative to HSCs. Relative YFP+ frequencies of mature myeloid cells (My), B-cells (B), and T cells (T) to HSCs in the bone marrow (BM) (G) and peripheral blood (H). All data represent mean ± standard deviation. In panels A-D, *P < .05, **P < .01, and ***P < .001 (1-way ANOVA with post hoc Tukey’s multiple comparison test against all other groups). In panels E-H, *P < .05, **P < .01, and ***P < .001 (2-way ANOVA with post hoc Tukey’s multiple comparison test against all other groups). #P < .05, ##P < .01 (post hoc Tukey’s multiple comparison test between HSCs and MPP/HPC1) in panel E and between platelets (Plt) and B/T cells in panel H.$

HSCs labeled by Krt18-CreER contribute to steady-state hematopoiesis. (A-D) Longitudinal analysis of YFP⁺ fraction in the indicated populations at 1 (A), 4 (B), 26 (C), and ∼52 (D) weeks after tamoxifen treatment (n = 4-6). (E-F) Frequencies of YFP⁺ cells in each population relative to HSCs. (E) Frequencies of YFP⁺ cells within the LSK fraction relative to HSCs. (F) Relative frequencies of YFP⁺ myeloid and lymphoid progenitor cells relative to HSCs. Relative YFP⁺ frequencies of mature myeloid cells (My), B-cells (B), and T cells (T) to HSCs in the bone marrow (BM) (G) and peripheral blood (H). All data represent mean ± standard deviation. In panels A-D, *P < .05, **P < .01, and ***P < .001 (1-way ANOVA with post hoc Tukey’s multiple comparison test against all other groups). In panels E-H, *P < .05, **P < .01, and ***P < .001 (2-way ANOVA with post hoc Tukey’s multiple comparison test against all other groups). #P < .05, ##P < .01 (post hoc Tukey’s multiple comparison test between HSCs and MPP/HPC1) in panel E and between platelets (Plt) and B/T cells in panel H.

This Feature Is Available To Subscribers Only